Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress
29 janv. 2024 08h05 HE
|
Palisade Bio, Inc.
– Preclinical data demonstrated PALI-2108 to be safe and well tolerated – PALI-2108 is orally delivered and colon activated allowing for local activity with low systemic exposure – Company...
Global Inflammatory Bowel Disease Treatment Market Set to Soar with Predicted 5.84% CAGR by 2034
29 janv. 2024 05h04 HE
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Inflammatory Bowel Disease Treatment Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. ...
Acute Pancreatitis Global Market Report 2024: Market to Surge to $7.41 Billion by 2028, Driven by Technological Advances and Growing Health Concerns - Long-term Forecast to 2033
25 janv. 2024 09h14 HE
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Acute Pancreatitis Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The latest acute pancreatitis market...
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
24 janv. 2024 02h30 HE
|
Abivax
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 PARIS,...
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
09 janv. 2024 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD),...
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
08 janv. 2024 08h00 HE
|
Biora Therapeutics, Inc.
SAD/MAD study to evaluate safety and PK/PD of BT-600 drug-device combination, including concentrations in colon tissue
Global Stoma/Ostomy Care Market Report, 2022-2023 and 2024-2030 - Product Innovations and Advancements to Spur Market Expansion
08 janv. 2024 07h33 HE
|
Research and Markets
Dublin, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The "Stoma/Ostomy Care - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Stoma/Ostomy Care Products...
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
27 déc. 2023 06h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
19 déc. 2023 08h00 HE
|
Biora Therapeutics, Inc.
Biora's latest patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract.
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
06 déc. 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...